Understanding MGUS: Why Early Monitoring Can Be Life-Changing

Monoclonal Gammopathy of Undetermined Significance (MGUS) is a non-malignant, asymptomatic blood disorder in which plasma cells produce a monoclonal protein (m protein). While MGUS itself does not require treatment, it carries a steady risk of progression to multiple myeloma, an uncommon hematologic malignancy.

Despite advances in treatment, multiple myeloma remains incurable. Our experts in the Pentecost Myeloma Research Center (PMRC) are tackling this challenge in part by focusing on prevention of myeloma by developing acquiring a better understanding of MGUS and developing preventative strategies. This is the impetus of the Myeloma precursor state clinic (MGUS clinic).

Why is an MGUS Clinic Important?

Our clinic provides comprehensive monitoring and care for patients with MGUS, focusing on identifying risk factors and facilitating the early diagnosis of multiple myeloma. The goals of the MGUS clinic are to:

1. Establish a dedicated and uniform management principle for the diagnosis and monitoring of patients with MGUS
2. Enable the molecular characterization of the precursor condition to better understand/predict the risk of multiple myeloma development
3. Facilitate prevention clinical trials in this patient population

With individualized risk stratification, the clinic utilizes advanced predictive models to tailor follow-up plans to each patient's unique risk profile. Patients benefit from specialized monitoring, with regular surveillance designed to detect evolving disease early. In addition, eligible patients may gain access to clinical trials focused on prevention or early intervention strategies.

Prevention strategies for MGUS to multiple myeloma progression are not proven at this time, but several strategies, including dietary intervention, could be investigated.

Rachid Baz, MD

Who is Most at Risk for MGUS?

MGUS risk can be significantly higher in certain groups, including:

• African Americans
• Men
• Individuals with a family history of MGUS or B-cell lymphoma

Moffitt provides infrastructure to systematically identify, monitor, and intervene for these patients.

Collaboration between primary care providers and specialists is essential to ensuring timely, life-saving interventions for patients facing potential cancer diagnoses. By responding proactively to abnormal blood test results and concerning symptoms, we can work together to identify cancer earlier, initiate treatment faster, and significantly improve patient outcomes.

Working with Moffitt’s MGUS Clinic

Our multidisciplinary team of experts in the Malignant Hematology Program brings deep expertise and a collaborative spirit to every case, ensuring your patients receive the highest standard of care from diagnosis through survivorship.

Let’s partner to give patients their best chance in the fight against blood cancers. To refer a patient with known or suspected MGUS, fill out our online referral form or contact a physician liaison at Physician.Relations@Moffitt.org for assistance.